There are 2789 resources available
117O - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials
Presenter: Valentina Guarneri
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
118O - Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
Presenter: Lucia Del Mastro
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Yes
Presenter: Sara Lonardi
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
No
Presenter: Rodrigo Dienstmann
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Q&A
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
Presenter: Christian Pfister
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast